Katharine J Bar - Faculty Biosketch

Katharine J Bar, MD

Associate Professor of Medicine (Infectious Diseases)

Attending Physician, Infectious Diseases, Hospital of the University of Pennsylvania

Physician, International Travel Medicine Clinic, Perelman Center for Advanced Medicine

Director, Penn CFAR Viral and Molecular Core

3 5f

Department: Medicine

4 1 b

46 Contact information
44

502 D Johnson Pavilion
3a 3610 Hamilton Walk
Philadelphia, PA 19104-6073

30 Office: (215) 573-8497
34 Fax: (215) 349-5111
24

Email:
bark@pennmedicine.upenn.edu

4 3 23

1f Graduate Group Affiliations 8

Cell and Molecular Biology
Immunology

3 3 2 4 b 1f

13 Education:
21 7 BA 35 (Biochemistry and African History, Honors) c
3e Northwestern University, Evanston, IL, 1997.
21 7 MD c
4e University of Iowa College of Medicine, Iowa City, IA, 2002.
c

3 3 21

1f Post-Graduate Training
24 82 Intern and Resident, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, 2002-2005.
24 85 Chief Medical Resident, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, 2005-2006.
24 96 Fellow Division of Infectious Diseases, Department of Medicine, University of Alabama School of Medicine, Birmingham, AL, 2006-2009.
24 bb Clinical and Post Doctoral Research Fellow, Division of Infectious Diseases, Department of Medicine, University of Alabama School of Medicine, Birmingham, AL, 2007-2009.
24 9b Chief Fellow Division of Infectious Disease, Department of Medicine, University of Alabama School of Medicine, Birmingham, AL, 2008-2009.
c

3 25

17 Certifications
28 47 Diplomate, National Board of Medical Examiners, 2003.
28 53 Diplomate, American Board of Internal Medicine, No. 265961, 2005.
28 7b Diplomate, American Board of Internal Medicine, Subspecialty Board, Infectious Disease, No. 265961, 2009.
c

3 8d Permanent link
2 29

b6 > Perelman School of Medicine > Faculty > Details a

1e 1d

Description of Clinical Expertise

39 HIV care, general infectious disease care
71

Description of Research Expertise

74 The Bar Lab studies novel approaches to HIV prevention and cure. Our current research focuses on:
7d (i) characterizing the viral dynamics and host immune responses during virus suppression and treatment interruption,
5f (ii) developing NHP models that faithfully recapitulate HIV-1 latency and rebound, and
35 (iii) developing antibody-based interventions.
e 29

Selected Publications

128 Murphy T, Kelly M, Shimagaki KS, DeStefanis T, Galeotos G, Lee M, Wei Q, Novak J, Bar KJ, Barton JP, Lynch RM.: Dual Role of Glycosylation in Resistance to CD4-binding Site Broadly Neutralizing Antibodies. J Virol Mar 2026.

208 Pache L, Bui JK, Klouser LM, Fennessey CM, Noyola AC, Einhaus T, Zhu H, Stensland L, Leguizamo I, Koroma AA, Teriete P, Chang WLW, Hyrien O, Duggan NN, Heimann D, Pérez-Osorio AC, Bar KJ, Cosford ND, Keele BF, Hartigan-O'Connor DJ, Farzan M, Gardner MR, Jerome KR, Chanda SK, Kiem HP, Peterson CW. : Smac mimetic combined with eCD4-Ig reverses latency without reducing SHIV reservoirs in rhesus macaques. J Clin Invest 136((6):e187961), Mar 2026.

299 Ndung'u T, Dong KL, Colby DJ, Deeks SG, Cotton MF, Dubé K, Goulder PJ, Julg B, Nsubuga M, Ajibola G, Bar KJ, Bengu N, Bwakura-Dangarembizi M, Caskey M, Cromhout G, Kekitiinwa AR, Kilembe W, Kuhn L, Likhitwonnawut U, Mgodi NM, Persaud D, Peluso MJ, Rasmussen TA, Romo M, Sacdalan C, Samaneka W, Shapiro R, Søgaard OS, Tudor-Williams G, Wambui C, Tressler R, Lewin SR, Crowell TA, Kasprowicz VO, Trautmann L.: 2nd ATI Consensus Workshop. Recommendations from the 2nd Consensus Workshop on Analytical Treatment Interruption in HIV Research Trials. Lancet HIV S2352-3018(25): 00373-X, Feb 2026.

122 Murray J, Einhaus T, Radtke S, Bar KJ, Peterson CW, Kiem HP. : Engraftment of gene-edited hematopoietic stem cells after antibody-drug conjugate conditioning in nonhuman primates. Blood Adv 10(4): 1094-1105, Feb 2026.

19b Taiwo BO, Zheng Y, Rodriguez K, Burke L, Reeves JD, Scarsi KK, Gama L, Petropoulos CJ, Belaunzaran-Zamudio PF, Wannamaker P, D'Amico R, Rathod P, Bar KJ, Tebas P; A5357 Study Team. : Phase 2 Trial of Long-Acting Cabotegravir and VRC07-523LS for Viral Suppression in Adults With HIV-1: ACTG A5357. Clin Infect Dis 82(1): 100-108, Feb 2026.

307 Habib R, Roark RS, Li H, Connell AJ, Hogarty MP, Wagh K, Wang S, Marchitto L, Skelly AN, Carey JW, Sowers KJ, Ayyanathan K, Plante SJ, Bibollet-Ruche F, Park Y, Agostino CJ, Singh A, Martella CL, Lewis E, Rando JM, Chohan N, Lora J, Ding W, Campion MS, Zhao C, Liu W, Li Y, Li X, Liang B, Chowdhury RR, Amereh K, Van Itallie E, Sheng Z, Ghosh AR, Bar KJ, Williams WB, Wiehe K, Saunders KO, Edwards RJ, Cain DW, Lewis MG, Batista FD, Burton DR, Andrabi R, Kulp DW, Haynes BF, Korber B, Shapiro L, Kwong PD, Hahn BH, Shaw GM.: Env-antibody coevolution identifies B cell priming as the principal bottleneck to HIV V2 apex broadly neutralizing antibody development. Sci Immunol 11(116): eadz3933, Feb 2026.

183 Smith NM, Ho BM, Bar KJ, Gama L, Dziubla G, Koup RA, Pensiero M, Serebryannyy L, Caskey M, Wilkin TJ, Wood TD, Morse GD, Venuto CS, Cha R, Ma Q.: Enhanced Clearance of HIV-1 Broadly Neutralizing Antibody VRC07-523-LS During Viremia: Influences on Trial Design and Analysis. Clin Transl Sci 19(2): e70488, Feb 2026.

14d Podgorski RM, Yarmahmoodi A, Baak S, Warfield R, Robinson JA, Roof J, Caocci M, Fazelinia H, Spruce LA, Bar KJ, Burdo TH.: SHIV.D Infection Alters Production and Protein Composition of Myeloid-Derived Extracellular Vesicles. Int J Mol Sci 27(2): 966, Jan 2026.

18c Pampena MB, Samer S, Viox EG, Nguyen K, Deleage C, Kuri-Cervantes L, Regan J, Wu VH, Docken S, Safrit JT, Bar KJ, Keele BF, Davenport MP, Paiardini M, Betts MR. : Therapeutic CD8+ T cell tissue retention and immunomodulation during ART interruption fail to prevent SIV rebound. Proc Natl Acad Sci U S A. 122(33), Aug 2025.

295 Karuna S, Laher F, Dadabhai S, Yu PC, Grove D, Orrell C, Makhema J, Hosseinipour MC, Mathew CA, Brumskine W, Mgodi N, Andrew P, Gama L, Karg C, Broder G, Baepanye K, Lucas J, Andrasik M, Takuva S, Villaran M, Takalani A, Tressler R, Soto-Torres L, Woodward Davis AS, Dhai A, Sanne IM, Cohen MS, Corey L, Gray G, deCamp AC, Bar KJ: Analytical treatment interruption among women with HIV in southern Africa who received VRC01 or placebo in the Antibody Mediated Prevention Study: ATI stakeholder engagement, implementation and early clinical data. J Int AIDS Soc 28(6): e26495, June 2025.

2c

7 1d

2c back to top
26 Last updated: 03/19/2026
34 The Trustees of the University of Pennsylvania c